# BioVie Inc. (BIVI) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/BIVI
## Company Profile
- Ticker: BIVI
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 2.03 USD
- Market cap: 12821126.299999999 USD
- Last updated: 2026-09-03
## Business Overview
BioVie is a biotechnology company focused on neurodegeneration, inflammation, and chronic disease biology. Its story has centered on trying to build a therapeutic platform in areas with large unmet need but high development risk.
## Why The Stock Is Moving

As of Sep 3, 2026, BIVI was little changed and closed at $2.03. No new same-company headline was identified in the current news window.

## Geographic Base

BioVie is headquartered in the United States and listed on NASDAQ. It sits in small-cap biotechnology.

## Business Model

The company depends on clinical progress, strategic focus, and financing discipline. Investors usually watch early data, pipeline direction, and whether the company can preserve enough runway.

## Landscape Position

BioVie occupies a speculative small-cap biotech niche. It is a catalyst-sensitive story where the market is still waiting for a clear clinical breakthrough.

## Future Catalysts

- BioVie’s catalysts are azeliragon-related programs and any strategic or clinical update that clarifies the company’s path. The next step matters because the company still needs a strong human-data signal.

## Recent News
- 2026-08-31 12:00 EST — [BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID](https://biopharmsignal.com/news/BIVI/biovie-announces-completion-of-treatment-phase-of-address-lc-trial-of-bezisterim-0c17937c) — Source: BioVie Inc.
- 2026-08-06 11:30 EST — [BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease](https://biopharmsignal.com/news/BIVI/biovie-announces-topline-results-of-phase-2-sunrise-pd-trial-of-bezisterim-in-ea-e54e169b) — Source: BioVie Inc.
- 2026-05-27 12:00 EST — [Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2](https://biopharmsignal.com/news/BIVI/join-biovie-s-exclusive-live-investor-webinar-and-q-and-a-session-on-june-2-972b03ed) — Source: BioVie Inc.
- 2026-05-26 12:00 EST — [BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID](https://biopharmsignal.com/news/BIVI/biovie-announces-full-enrollment-of-the-address-lc-trial-of-bezisterim-for-the-t-bacc426e) — Source: BioVie Inc.
- 2026-05-18 12:00 EST — [BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease](https://biopharmsignal.com/news/BIVI/biovie-announces-completion-of-phase-2-sunrise-pd-trial-in-early-stage-parkinson-5865bdf4) — Source: BioVie Inc.